Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with diagnosis of Type 2 Diabetes Mellitus, who are experiencing inadequate glycemic control and receiving treatment with a stable dose of a single oral antidiabetic medication~* Body mass index (BMI) 17 to 40 kg/ m2 inclusive~* Subjects with an HbA1c between 7.0% and 10.0% at Screening~* Creatinine clearance \>30 mL/min (calculated using the Cockcroft-Gault formula)~Exclusion Criteria:~* History of type 1 diabetes mellitus~* Female subject is pregnant, lactating, or \<6 weeks postpartum~* Clinically significant cardiovascular and/or cerebrovascular disease~* Current ongoing symptomatic biliary disease, clinical signs or symptoms of pancreatitis, or a history of chronic or acute pancreatitis, as determined by the investigator~* Serum amylase \>=3 ×ULN and/or serum lipase \>=2 × ULN and/or subject is experiencing any symptoms possibly related to pancreatitis~* Prior use of a GLP-1R agonist or DPP-IV inhibitor within 6 months before Screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albiglutide + Sulfonylurea (Type: ACTIVE_COMPARATOR): Albiglutide in combination with background sulfonylurea
- Albiglutide + Biguanide (Type: ACTIVE_COMPARATOR): Albiglutide in combination with background biguanide
- Albiglutide + Glinide (Type: ACTIVE_COMPARATOR): Albiglutide in combination with background glinide
- Albiglutide + Thiazolidinedione (Type: ACTIVE_COMPARATOR): Albiglutide in combination with background thiazolidinedione
- Albiglutide + Alpha-glucosidase inhibitor (Type: ACTIVE_COMPARATOR): Albiglutide in combination with background alpha-glucosidase inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).